Pharmaceuticals
Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases
HONG KONG, Oct. 30, 2020 /PRNewswire/ -- October 30, 2020, Ocumension Therapeutics (1477.HK) announced that the Company has entered into a collaboration and exclusive promotion agreement with Shandong Boan Biological Technology Co. Ltd., a wholly-owned subsidiary of Luye Pharma Group Ltd. to joi...
2020-10-30 10:54
6260
AGC Biologics and Horizon Therapeutics plc Expand Partnership
Horizon's TEPEZZA® (teprotumumab-trbw) treatment will be produced from AGC Biologics' new facility inBoulder, CO SEATTLE, Oct. 30, 2020 /PRNewswire/ -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced that its partnership wit...
2020-10-30 03:17
5038
Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide
SEOUL, South Korea, Oct. 29, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon, KRX: 069620) announced on October 26 that the collaborative clinical research agreement between Daewoong and Tufts Medical Center was signed to prepare for the phase 2 clinical study of DWRX2003 (active i...
2020-10-29 21:00
2235
Complete Data from Connect Biopharma's Phase 1b Study of CBP-201 Demonstrate Rapid, Early and Continuous Improvement in Patient Quality of Life and Atopic Dermatitis (AD) Symptoms
Results from study in adult patients with moderate-to-severe AD presented at EADV Congress SAN DIEGO and TAICANG, SUZHOU, China, Oct. 29, 2020 /PRNewswire/ -- Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune mo...
2020-10-29 19:00
1828
Asieris' APL-1501 Approved for Phase I Clinical Trial in Australia
SHANGHAI, Oct. 29, 2020 /PRNewswire/ -- Asieris Pharmaceuticals, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, today announced that Australian regulatory authorities have approved it...
2020-10-29 09:35
1973
CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate
* CStone to acquire exclusive rights for development and commercialization outsideSouth Korea for LCB71, an ROR1 antibody drug conjugate * Agreement adds to CStone's pipeline a potential first-in-class/best-in-class drug candidate with monotherapy and combination applications for a range of c...
2020-10-29 07:15
3672
BioInvent Completes First Licensing Agreement in Greater China, Advised by MSQ Ventures
NEW YORK, Oct. 29, 2020 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") announced today that its client, BioInvent International, AB ("BioInvent"), has successfully entered into a licensing agreement with CASI Pharmaceuticals, Inc. ("CASI") for the development and commercialization of BI-1206 in theGreat...
2020-10-29 02:51
2855
Daewoong Pharmaceutical's COVID-19 Treatment Candidate Also Highly Effective against Influenza Virus
SEOUL, South Korea, Oct. 28, 2020 /PRNewswire/ -- Daewoong Pharmaceutical, a South Korean pharmaceutical giant announced that its Covid-19 treatment candidate of sustained-release niclosamide (DWRX2003) also showed promising study results for a fight against the upcoming 'Twindemic' involving COV...
2020-10-28 22:36
1558
Yuyu Pharma Announces the Introduction of Anti-Bribery Management System to meet Global Standards
SEOUL, South Korea, Oct. 28, 2020 /PRNewswire/ -- On October 28, 2020, Yuyu Pharm (CEO Robert Wonsang Yu, KRX 000220) initiated steps to incorporate ISO 37001 Anti-bribery management system to strengthen the company's compliance system. During the introduction ceremony of ISO 37001 held at Yuyu P...
2020-10-28 21:00
1771
I-Mab Announces Upcoming Participation at November Conferences
SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences i...
2020-10-28 20:00
2719
MMI SpA Launches Breakthrough Technology, Advancing Robotic Microsurgery with the World's Smallest Wristed Surgical Instruments
First Procedures Performed with the Symani Surgical System CALCI, Italy, Oct. 28, 2020 /PRNewswire/ -- MMI SpA, an Italian company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today the CE Mark, launch and first human use of its Symani® Surgical Syste...
2020-10-28 20:00
3017
Yiling Pharmaceutical: Revenue and Net Profit Attributable to the Parent Company for the First Three Quarters Already Exceeded the Full Year 2019
SHIJIAZHUANG, China, Oct. 28, 2020 /PRNewswire/ -- On October 27, Yiling Pharmaceutical (002603.SZ) released its 2020 third quarter report. In the first three quarters of the year, Yiling Pharmaceutical achieved the total operating revenue of6.447 billion yuan (about US$962 million), a 48.31% yea...
2020-10-28 17:04
6586
APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clinical Trial in China for [18F]-APN-1607 Tau PET Imaging Tracer for Dementia
SUZHOU, China, Oct. 28, 2020 /PRNewswire/ -- APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA's positron emission tomography (PET) imaging tracer, [18F]-APN-1607, targeting abnorma...
2020-10-28 14:00
2285
Daewoong Pharmaceutical's Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 'Twindemic'
SEOUL, South Korea, Oct. 27, 2020 /PRNewswire/ -- Daewoong Pharmaceutical, a South Korean pharmaceutical giant announced that its Covid-19 treatment candidate of sustained-release niclosamide (DWRX2003) also showed promising study results for a fight against the upcoming 'Twindemic' involving COV...
2020-10-27 21:00
1264
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company will present the latest preclinical dat...
2020-10-27 20:05
4620
TVM Capital Life Science Announces Substantially Oversubscribed US$478 Million Final Closing of TVM Life Science Innovation II, largest fund in the firm's history
- The Fund continues the proven "Project Focused Company" investment strategy for early-stage drug development candidates - In addition, the Fund continues to invest in late-stage clinical biopharmaceutical companies, medical device companies and diagnostic companies MUNICH and MONTREAL, Oct. 27...
2020-10-27 20:00
2557
Sihuan Pharmaceutical (0460.HK) receives approval for its exclusive medical aesthetic product Letybo (botulinum toxin), A blockbuster product in a hundred-billion size market
HONG KONG, Oct. 27, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460) is pleased announce that "Type A Botulinum Toxin for Injection" (Letybo 100U), a product exclusively distributed by Sihuan Pharmaceutical, has officially received the marketing approval from the Natio...
2020-10-27 10:42
6373
Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study inthe United States. BioMUSE is a natur...
2020-10-27 10:03
3605
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of MDM2-p53 Inhibitor APG-115 in Combination with Immunotherapy for the Treatment of Patients with Advanced Liposarcoma or other Advanced Solid Tumors in China
SUZHOU, China and ROCKVILLE, Md., Oct. 27, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Eva...
2020-10-27 08:13
2378
CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)
* CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for development and commercialization outside ofGreater China * Agreement provides a pathway to bring CStone's sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1) to global patient communities by partnering ...
2020-10-27 07:23
3515
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
